Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 376 to 390 of 476 results for learning disabilities

  1. Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment (HTG701)

    Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance.

    HealthTech guidance
    Published
    15 November 2023
    View recommendations

    Sections for HTG701

  2. What training, support or interventions help to reduce caring-related accidents or incidents?

    confidence in caring, and their understanding of the health condition, disability or needs of the person they care for, so the committee...

    Research recommendation
    Published
    10 February 2020

  3. Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest (MIB112)

    NICE has developed a medtech innovation briefing (MIB) on Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest .

    Medtech innovation briefing
    Published
    18 July 2017

  4. Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)

    Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor-alpha inhibitor.

    Technology appraisal guidance
    Published
    26 October 2016
    View recommendations

    Sections for TA415

  5. Ixekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA718)

    Evidence-based recommendations on ixekizumab (Taltz) for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults.

    Technology appraisal guidance
    Published
    21 July 2021
    View recommendations

    Sections for TA718

  6. Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)

    NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .

    Medtech innovation briefing
    Published
    29 November 2016

  7. Fenfluramine for treating seizures associated with Dravet syndrome (TA808)

    Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Dravet syndrome in people aged 2 and older.

    Technology appraisal guidance
    Published
    8 July 2022
    View recommendations

    Sections for TA808

  8. Fremanezumab for preventing migraine (TA764)

    Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA764

  9. Digital technologies for delivering multidisciplinary weight-management services: early value assessment (HTG700)

    Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services.

    HealthTech guidance
    Last updated
    6 March 2024
    View recommendations

    Sections for HTG700

  10. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of a brief psychosocial intervention as reported by the IMPACT trial, but delivered by practitioners other than psychiatrists and in other settings, including primary care, to young people aged 12 to 18 years with mild or moderate to severe depression?

    struggle with the concepts of CBT and children and young people with learning disabilities or neurodevelopmental disorders. They made a...

    Research recommendation
    Published
    25 October 2019

  11. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of family therapy, psychodynamic psychotherapy and interpersonal psychotherapy for adolescents (IPT‑A) compared with each other and with individual CBT in young people aged 12 to 18 years with moderate to severe depression?

    struggle with the concepts of CBT and children and young people with learning disabilities or neurodevelopmental disorders. They made a...

    Research recommendation
    Published
    25 October 2019

  12. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of psychological therapies in children aged 5 to 11 years with mild or moderate to severe depression?

    struggle with the concepts of CBT and children and young people with learning disabilities or neurodevelopmental disorders. They made a...

    Research recommendation
    Published
    25 October 2019

  13. Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessment (HTG718)

    Early value assessment (EVA) guidance on digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD.

    HealthTech guidance
    Last updated
    17 September 2025
    View recommendations

    Sections for HTG718

  14. Infliximab and adalimumab for the treatment of Crohn's disease (TA187)

    Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults.

    Technology appraisal guidance
    Published
    19 May 2010
    View recommendations

    Sections for TA187

  15. Galcanezumab for preventing migraine (TA659)

    Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    18 November 2020
    View recommendations

    Sections for TA659